Meeting
2019 ASCO Annual Meeting
Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
Authors
Gregory J. Riely
Memorial Sloan Kettering Cancer Center, New York, NY
Gregory J. Riely , Christine Marie Lovly , Carlo GM Messina , Stefanie Bienert , Kimberly Alexander , William Pao , Shrujal Baxi , Robert Charles Doebele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9062)
DOI
10.1200/JCO.2019.37.15_suppl.9062
Abstract #
9062
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
First Author: Sarah B. Goldberg
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2019 ASCO Annual Meeting
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.
First Author: Peng Xie
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu